These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Structural determinants for affinity enhancement of a dual antagonist peptide entry inhibitor of human immunodeficiency virus type-1. Gopi H; Umashankara M; Pirrone V; LaLonde J; Madani N; Tuzer F; Baxter S; Zentner I; Cocklin S; Jawanda N; Miller SR; Schön A; Klein JC; Freire E; Krebs FC; Smith AB; Sodroski J; Chaiken I J Med Chem; 2008 May; 51(9):2638-47. PubMed ID: 18402432 [TBL] [Abstract][Full Text] [Related]
9. CD4 mimics targeting the mechanism of HIV entry. Yamada Y; Ochiai C; Yoshimura K; Tanaka T; Ohashi N; Narumi T; Nomura W; Harada S; Matsushita S; Tamamura H Bioorg Med Chem Lett; 2010 Jan; 20(1):354-8. PubMed ID: 19926478 [TBL] [Abstract][Full Text] [Related]
10. Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds. Madani N; Princiotto AM; Zhao C; Jahanbakhshsefidi F; Mertens M; Herschhorn A; Melillo B; Smith AB; Sodroski J J Virol; 2017 Feb; 91(3):. PubMed ID: 27881646 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions. Boussard C; Klimkait T; Mahmood N; Pritchard M; Gilbert IH Bioorg Med Chem Lett; 2004 May; 14(10):2673-6. PubMed ID: 15109676 [TBL] [Abstract][Full Text] [Related]
12. The C4 region as a target for HIV entry inhibitors--NMR mapping of the interacting segments of T20 and gp120. Moseri A; Biron Z; Arshava B; Scherf T; Naider F; Anglister J FEBS J; 2015 Dec; 282(24):4643-57. PubMed ID: 26432362 [TBL] [Abstract][Full Text] [Related]
15. Recent Progress in the Development of HIV-1 Entry Inhibitors: From Small Molecules to Potent Anti-HIV Agents. Suttisintong K; Kaewchangwat N; Thanayupong E; Nerungsi C; Srikun O; Pungpo P Curr Top Med Chem; 2019; 19(18):1599-1620. PubMed ID: 31424370 [TBL] [Abstract][Full Text] [Related]
16. Systematic Evaluation of Fluorination as Modification for Peptide-Based Fusion Inhibitors against HIV-1 Infection. Huhmann S; Nyakatura EK; Rohrhofer A; Moschner J; Schmidt B; Eichler J; Roth C; Koksch B Chembiochem; 2021 Dec; 22(24):3443-3451. PubMed ID: 34605595 [TBL] [Abstract][Full Text] [Related]
17. Design, synthesis and evaluation of peptide libraries as potential anti-HIV compounds, via inhibition of gp120/cell membrane interactions, using the gp120/cd4/fab17 crystal structure. Boussard C; Doyle VE; Mahmood N; Klimkait T; Pritchard M; Gilbert IH Eur J Med Chem; 2002 Nov; 37(11):883-90. PubMed ID: 12446047 [TBL] [Abstract][Full Text] [Related]
18. An effective conjugation strategy for designing short peptide-based HIV-1 fusion inhibitors. Liang G; Wang H; Chong H; Cheng S; Jiang X; He Y; Wang C; Liu K Org Biomol Chem; 2016 Aug; 14(33):7875-82. PubMed ID: 27454320 [TBL] [Abstract][Full Text] [Related]
19. HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor. Bashir T; Patgaonkar M; Kumar SC; Pasi A; Reddy KV PLoS One; 2015; 10(4):e0124839. PubMed ID: 25915507 [TBL] [Abstract][Full Text] [Related]
20. Peptides from second extracellular loop of C-C chemokine receptor type 5 (CCR5) inhibit diverse strains of HIV-1. Dogo-Isonagie C; Lam S; Gustchina E; Acharya P; Yang Y; Shahzad-ul-Hussan S; Clore GM; Kwong PD; Bewley CA J Biol Chem; 2012 Apr; 287(18):15076-86. PubMed ID: 22403408 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]